SPECT emerged as the winner in a head-to-head comparison of cost outcomes for patients evaluated for coronary artery disease (CAD) after a two-year follow-up. The cost of subsequent invasive procedures made rivals PET and coronary computed tomography angiography (CTA) more expensive.
Read more here.
